Adlai Nortye (NASDAQ:ANL) Shares Down 4.1% – What’s Next?

Posted by George Bondi on Oct 19th, 2026

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL – Get Free Report)’s stock price was down 4.1% on Monday. The company traded as low as $10.58 and last traded at $10.5790. Approximately 19,935 shares traded hands during mid-day trading, a decline of 95% from the average daily volume of 368,481 shares. The stock had previously closed at $11.03.

Analysts Set New Price Targets

A number of research firms have recently issued reports on ANL. Jefferies Financial Group upgraded shares of Adlai Nortye to a “strong-buy” rating in a report on Monday, October 5th. Loop Capital set a $49.00 price objective on Adlai Nortye in a report on Tuesday, September 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Adlai Nortye in a report on Monday, October 12th. Wall Street Zen upgraded shares of Adlai Nortye from a “hold” rating to a “buy” rating in a research note on Saturday, October 3rd. Finally, Cantor Fitzgerald started coverage on Adlai Nortye in a research note on Monday, June 22nd. They set an “overweight” rating for the company. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Adlai Nortye currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.50.

Get Our Latest Stock Analysis on Adlai Nortye

Adlai Nortye Price Performance

The company’s 50-day moving average is $14.44 and its 200-day moving average is $12.75.

Insiders Place Their Bets

In other news, Director Ping Ji sold 10,000 shares of the business’s stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $15.99, for a total value of $159,900.00. Following the sale, the director owned 121,453 shares in the company, valued at approximately $1,942,033.47. The trade was a 7.61% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Xiaofeng Ye sold 6,000 shares of the business’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $13.98, for a total transaction of $83,880.00. Following the completion of the transaction, the chief financial officer owned 153,424 shares in the company, valued at approximately $2,144,867.52. This trade represents a 3.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 26,881 shares of company stock valued at $411,060.

Institutional Trading of Adlai Nortye

A number of hedge funds and other institutional investors have recently modified their holdings of ANL. Braidwell LP bought a new stake in shares of Adlai Nortye during the second quarter worth $9,145,000. Boone Capital Management LLC bought a new position in Adlai Nortye during the 2nd quarter worth approximately $2,971,000. Affinity Asset Advisors LLC bought a new stake in shares of Adlai Nortye in the 1st quarter valued at $1,140,000. ADAR1 Capital Management LLC bought a new stake in shares of Adlai Nortye in the first quarter worth about $816,000. Finally, Seven Fleet Capital Management LP bought a new stake in Adlai Nortye during the 2nd quarter worth approximately $1,302,000. Institutional investors and hedge funds own 35.21% of the company’s stock.

About Adlai Nortye

(Get Free Report)

Adlai Nortye Ltd. (NASDAQ: ANL) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cancer and other serious diseases. The company’s research and development programs are centered on immuno-oncology and targeted therapies intended to address unmet medical needs.

Adlai Nortye’s pipeline has included buparlisib, an oral pan-PI3K inhibitor being studied in oncology, as well as AN0025, an investigational EP4 antagonist designed to affect pathways involved in tumor growth and immune response.